Skip to main content
Michael Allen Pulsipher

Michael Allen Pulsipher, MD

Languages spoken: English, Japanese

Clinical Locations

  • Clinic 2C/BMT, Blood and Marrow Transplant

    801-585-0100
  • Pediatric Hematology/Oncology

    801-662-4830
  • Pediatric Hematology/Oncology

    801-662-4700
  • Dr. Pulsipher is currently the Division Chief of the Pediatric Hematology at Intermountain Primary Children’s Hospital and Oncology, Director of the Children’s and Adolescent Cancer Initiative at Huntsman Cancer Institute and a Presidential Chair in Pediatric Oncology and Hematology at the University of Utah.

    Dr. Pulsipher is the immediate past Group Chair of the Pediatric Transplantation and Cellular Therapy Consortium, an 86-member international clinical trials group, and is recognized as a leading influence in his field, receiving the PTCTC Lifetime Achievement Award in 2020.

    He is currently principal or co-principal investigator of six national, multi-center studies and a co-investigator on multiple additional clinical trials. Dr. Pulsipher has authored more than 260 articles in peer-reviewed journals and written 17 book chapters. His research interests include allogeneic transplantation and cell therapy for acute leukemias, especially ALL, where he is running national research trials aimed at testing haploidentical approaches and assessing the role of NGS-MRD in identifying patients able to undergo less intensive BMT approaches. Dr. Pulsipher’s work in cell therapy helped lead to the FDA approval of the first CART cell treatment, tisagenlecleucel, and he continues to run trials in CAR T, NK, and Viral Specific T-cell therapies.

    Dr. Pulsipher has also done extensive work in reduced toxicity approaches to transplantation of both malignant and non-malignant disorders, and has run national protocols for patients with immunodeficiencies, HLH, and bone marrow failure. Finally, he has run several large trials assessing the safety and Quality of Life of pediatric bone marrow donors and is he currently running a large national trial looking at the psychological well-being of donor and recipient families as they go through the transplant process.



    For questions regarding Dr. Pulsipher's adult practice at the Huntsman Cancer Institute, or for questions about any of our clinical programs and for assistance identifying the right Hematology specialist for you or your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-4652, or www. huntsmancancer. org

    For questions regarding Dr. Pulsipher's pediatric practice and the Blood and Marrow Transplant Program at Primary Children's Medical Center, please call (801) 662-4830, or please feel free to contact Stephanie Mortensen, RN-C, Coordinator at Stephanie. Mortensen@imail. org or Shawnda Ussery, RN-C, Coordinator at Shawnda. Ussery@imail. org

    Specialties

    Board Certification and Academic Information

    Academic Departments Pediatrics - Primary
    Academic Divisions
  • Dr. Pulsipher is currently the Division Chief of the Pediatric Hematology at Intermountain Primary Children’s Hospital and Oncology, Director of the Children’s and Adolescent Cancer Initiative at Huntsman Cancer Institute and a Presidential Chair in Pediatric Oncology and Hematology at the University of Utah.

    Dr. Pulsipher is the immediate past Group Chair of the Pediatric Transplantation and Cellular Therapy Consortium, an 86-member international clinical trials group, and is recognized as a leading influence in his field, receiving the PTCTC Lifetime Achievement Award in 2020.

    He is currently principal or co-principal investigator of six national, multi-center studies and a co-investigator on multiple additional clinical trials. Dr. Pulsipher has authored more than 260 articles in peer-reviewed journals and written 17 book chapters. His research interests include allogeneic transplantation and cell therapy for acute leukemias, especially ALL, where he is running national research trials aimed at testing haploidentical approaches and assessing the role of NGS-MRD in identifying patients able to undergo less intensive BMT approaches. Dr. Pulsipher’s work in cell therapy helped lead to the FDA approval of the first CART cell treatment, tisagenlecleucel, and he continues to run trials in CAR T, NK, and Viral Specific T-cell therapies.

    Dr. Pulsipher has also done extensive work in reduced toxicity approaches to transplantation of both malignant and non-malignant disorders, and has run national protocols for patients with immunodeficiencies, HLH, and bone marrow failure. Finally, he has run several large trials assessing the safety and Quality of Life of pediatric bone marrow donors and is he currently running a large national trial looking at the psychological well-being of donor and recipient families as they go through the transplant process.



    For questions regarding Dr. Pulsipher's adult practice at the Huntsman Cancer Institute, or for questions about any of our clinical programs and for assistance identifying the right Hematology specialist for you or your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-4652, or http://www. huntsmancancer. org

    For questions regarding Dr. Pulsipher's pediatric practice and the Blood and Marrow Transplant Program at Primary Children's Medical Center, please call (801) 662-4830, or please feel free to contact Stephanie Mortensen, RN-C, Coordinator at Stephanie. Mortensen@imail. org or Shawnda Ussery, RN-C, Coordinator at Shawnda. Ussery@imail. org

    Board Certification and Academic Information

    Academic Departments Pediatrics -Primary
    Academic Divisions

    Education history

    Fellowship Pediatric Hematology/Oncology - Dana-Farber Cancer Institute/Boston Children’s Hospital Fellow
    Pediatrics - Children's Hospital of Philadelphia Resident
    Internship Pediatrics - Children's Hospital of Philadelphia Intern
    Medicine - Stanford University School of Medicine M.D.
    Undergraduate Chemistry - Brigham Young University B.A.